Ceftriaxone in the treatment of acute and subacute human brucellosis.
A total of 14 adults were diagnosed as having brucellosis by clinical means, serology and blood culture. The first patient to be treated failed to respond to 2 g/day intravenous ceftriaxone, therefore, subsequent patients were treated intravenously, twice daily with 2 g ceftriaxone. Immediate clinical response was seen in nine (69.2%) of the patients. Therapy was changed to tetracycline plus streptomycin in the remaining four (30.8%) patients because of lack of response after 5 days. It is concluded that ceftriaxone may be considered a second-line therapy for brucellosis in patients who cannot be given conventional therapy. Further evaluation of ceftriaxone, either alone or preferably in combination with streptomycin or rifampicin on a larger scale, is indicated.
al-Idrissi
H Y
HY
College of Medicine and Medical Sciences, King Faisal University, Dammam, Saudi Arabia.
Uwaydah
A K
AK
Danso
K T
KT
Qutub
H
H
al-Mousa
M S
MS
D000208:Acute Disease; D000372:Agglutination Tests; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002002:Brucella / Q000187:drug effects / Q000302:isolation & purification; D002006:Brucellosis / Q000175:diagnosis / Q000188:drug therapy*; D002443:Ceftriaxone / Q000627:therapeutic use*; D006801:Humans; D008826:Microbial Sensitivity Tests
D000900:Anti-Bacterial Agents; D002443:Ceftriaxone